Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
09926 AKESO
RTNominal unchange46.650 0.000 (0.000%)
Others

04/08/2021 11:33

Akeso (09926) gets clinical trial approval from NMPA

[ET Net News Agency, 4 August 2021] Akeso, Inc. (09926) said the company has received
the approval from the National Medical Products Administration of the People's Republic of
China to initiate an open-label, multicentre phase Ib/II clinical trial for the global
first-in-class novel drug Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and
development code: AK104), an immuno-oncology therapy independently developed by the
company, in combination with VEGFR-2 monoclonal antibody (research and development code:
AK109) for treatment of advanced solid tumours.
The company has previously initiated a phase I clinical trial of AK109 for treatment of
advanced solid tumours and phase Ib/II clinical trial of AK109 in combination with
Cadonilimab for treatment of gastric cancer in China. (RC)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.